湖南南新制药股份有限公司2026年第一次临时股东会决议公告

Group 1 - The company held its first extraordinary general meeting of shareholders on February 11, 2026, in Guangzhou, with no resolutions being rejected [2] - The meeting was convened by the board of directors and chaired by Mr. Zhang Shixi, using a combination of on-site and online voting methods, complying with relevant laws and regulations [2][3] - The company successfully elected independent directors to the second board of directors during the meeting [4][5] Group 2 - Mr. Zhang Shixi submitted his resignation as general manager due to work adjustments, effective immediately upon delivery to the board [9] - The board appointed Mr. Chen Jianxu as the new general manager, with a term lasting until the end of the current board's term [9][12] - Mr. Chen Jianxu has a background in the pharmaceutical industry and has held various positions in reputable companies, ensuring his qualifications meet legal and regulatory requirements [13][14] Group 3 - The company plans to publicly transfer part of its accounts receivable held by a subsidiary through the Hunan United Property Exchange [15][16] - The total accounts receivable to be transferred amounts to 489.784 million yuan, with a provision for bad debts of 459.7945 million yuan, resulting in a book value of 29.9895 million yuan [17][20] - The transaction aims to optimize the company's asset structure and improve liquidity, with the final transaction price to be determined through public bidding [27][24]